The US Advisory Committee on Immunization Practices (ACIP) has voted to recommend the use of respiratory syncytial virus (RSV ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Guidelines from the Advisory Committee on Immunization Practices help physicians decide what vaccines to recommend to patients and are also used for determining insurance coverage in the U.S. The ...

Arexvy, already approved in over 60 countries, was supported by trial data showing safety and immune response in the 50–59 age group. GSK said more than 13 million adults in the US fall into this ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...